Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRTX Cortexyme	$1.78 +4.1%	$1.24	$1.78 ▼ $40.66	$53.67M	1.4	620,672 shs	370,847 shs
DNLI Denali Therapeutics	$14.52 -5.4%	$14.25	$10.57 ▼ $33.33	$2.23B	1.33	1.14 million shs	1.69 million shs
EDIT Editas Medicine	$2.88 -5.9%	$1.98	$0.91 ▼ $6.05	$256.16M	2.15	2.65 million shs	2.25 million shs
FATE Fate Therapeutics	$1.15 -0.9%	$1.20	$0.66 ▼ $5.92	$132.94M	2.18	2.22 million shs	1.04 million shs
RGNX REGENXBIO	$8.68 -4.2%	$8.90	$5.04 ▼ $15.36	$454.45M	1.06	926,815 shs	402,889 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRTX Cortexyme	+4.09%	+10.56%	+48.33%	+76.24%	+147.22%
DNLI Denali Therapeutics	-5.41%	-1.19%	-4.41%	+14.33%	-32.93%
EDIT Editas Medicine	-5.88%	+11.41%	+41.87%	+121.54%	-43.31%
FATE Fate Therapeutics	-0.86%	+0.44%	-25.81%	+8.49%	-63.14%
RGNX REGENXBIO	-4.19%	-0.57%	-14.90%	+47.37%	-19.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRTX Cortexyme	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	4.639 of 5 stars	4.5	1.0	0.0	4.7	3.3	3.3	0.0
EDIT Editas Medicine	4.2705 of 5 stars	3.2	2.0	0.0	4.3	3.8	2.5	0.6
FATE Fate Therapeutics	3.6114 of 5 stars	3.1	1.0	0.0	4.7	1.7	1.7	0.6
RGNX REGENXBIO	4.0749 of 5 stars	3.4	1.0	0.0	4.6	1.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRTX Cortexyme	0.00	N/A	N/A	N/A
DNLI Denali Therapeutics	3.06	Buy	$33.71	132.19% Upside
EDIT Editas Medicine	2.31	Hold	$4.70	63.19% Upside
FATE Fate Therapeutics	2.13	Hold	$3.83	233.33% Upside
RGNX REGENXBIO	2.83	Moderate Buy	$31.63	264.34% Upside

Current Analyst Ratings Breakdown

Latest DNLI, FATE, RGNX, CRTX, and EDIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/9/2025	RGNX REGENXBIO	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$52.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
4/29/2025	EDIT Editas Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRTX Cortexyme	N/A	N/A	N/A	N/A	$3.97 per share	N/A
DNLI Denali Therapeutics	$330.53M	6.38	N/A	N/A	$8.53 per share	1.70
EDIT Editas Medicine	$32.31M	7.46	N/A	N/A	$1.63 per share	1.77
FATE Fate Therapeutics	$13.63M	9.67	N/A	N/A	$2.80 per share	0.41
RGNX REGENXBIO	$83.33M	5.22	N/A	N/A	$5.24 per share	1.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRTX Cortexyme	-$89.94M	-$2.97	N/A	N/A	N/A	N/A	-70.96%	-63.53%	N/A
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/6/2025 (Estimated)
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
RGNX REGENXBIO	-$227.10M	-$3.11	N/A	N/A	N/A	-100.62%	-53.29%	-30.84%	8/7/2025 (Estimated)

Latest DNLI, FATE, RGNX, CRTX, and EDIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	DNLI Denali Therapeutics	-$0.73	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	RGNX REGENXBIO	-$1.13	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	EDIT Editas Medicine	-$0.40	N/A	N/A	N/A	$1.81 million	N/A
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/12/2025	Q1 2025	RGNX REGENXBIO	$0.41	$0.12	-$0.29	$0.12	$105.35 million	$89.01 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRTX Cortexyme	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
RGNX REGENXBIO	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRTX Cortexyme	N/A	9.92	9.92
DNLI Denali Therapeutics	N/A	9.56	9.56
EDIT Editas Medicine	N/A	3.08	3.08
FATE Fate Therapeutics	N/A	8.81	8.81
RGNX REGENXBIO	N/A	2.93	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRTX Cortexyme	63.18%
DNLI Denali Therapeutics	92.92%
EDIT Editas Medicine	71.90%
FATE Fate Therapeutics	97.54%
RGNX REGENXBIO	88.08%

Insider Ownership

Company	Insider Ownership
CRTX Cortexyme	27.90%
DNLI Denali Therapeutics	12.50%
EDIT Editas Medicine	2.10%
FATE Fate Therapeutics	5.51%
RGNX REGENXBIO	12.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRTX Cortexyme	55	30.15 million	21.74 million	Not Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
EDIT Editas Medicine	230	83.71 million	81.96 million	Optionable
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
RGNX REGENXBIO	370	50.16 million	43.75 million	Optionable

DNLI, FATE, RGNX, CRTX, and EDIT Headlines

Recent News About These Companies

REGENXBIO Announces Publication of Preclinical Results Demonstrating ...

July 11 at 9:10 PM | morningstar.comM

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

July 10 at 12:04 PM | prnewswire.com

RGNX | REGENXBIO Inc. Annual Income Statement - MarketWatch

July 6, 2025 | marketwatch.com

Janney Montgomery Scott LLC Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)

July 4, 2025 | marketbeat.com

REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

June 30, 2025 | marketbeat.com

Assenagon Asset Management S.A. Sells 283,399 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

June 16, 2025 | marketbeat.com

A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts

June 9, 2025 | benzinga.com

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

June 6, 2025 | seekingalpha.com

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

June 6, 2025 | biopharmadive.comB

RegeNXBio shares fall, despite positive new data on RGX-202

June 6, 2025 | thepharmaletter.comT

Regenxbio’s Duchenne gene therapy data positive as shares falter

June 5, 2025 | bioworld.comB

Regenxbio Fails To Best Sarepta’s Elevidys With New Data for DMD Gene Therapy

June 5, 2025 | biospace.comB

REGENXBIO updates Phase 1/2 data for Duchenne candidate

June 5, 2025 | msn.com

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

June 5, 2025 | benzinga.com

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

June 5, 2025 | prnewswire.com

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

June 2, 2025 | prnewswire.com

Regenxbio at RBC Conference: Strategic Moves and Clinical Progress

May 22, 2025 | investing.com

REGENXBIO Inc.: REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 20, 2025 | finanznachrichten.de

REGENXBIO announces royalty monetization agreement for up to $250M

May 20, 2025 | msn.com

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 19, 2025 | prnewswire.com

REGENXBIO Inc. (NASDAQ:RGNX) Director Sells $162,961.82 in Stock

May 15, 2025 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

DNLI, FATE, RGNX, CRTX, and EDIT Company Descriptions

Cortexyme NASDAQ:CRTX

$1.78 +0.07 (+4.09%)

As of 07/10/2025

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Denali Therapeutics NASDAQ:DNLI

$14.52 -0.83 (-5.41%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$14.52 0.00 (-0.03%)

As of 07/11/2025 07:47 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$2.88 -0.18 (-5.88%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$2.90 +0.02 (+0.87%)

As of 07/11/2025 07:58 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Fate Therapeutics NASDAQ:FATE

$1.15 -0.01 (-0.86%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$1.14 0.00 (-0.43%)

As of 07/11/2025 07:57 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

REGENXBIO NASDAQ:RGNX

$8.68 -0.38 (-4.19%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$8.85 +0.17 (+1.95%)

As of 07/11/2025 07:56 PM Eastern

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time